Galapagos huge outperformer in European biotech sector

In the past years Galapagos was a very good choice for investors. The stock was the past 10 years with a return of 1201 percent one of the larger outperformers of her peer group. Shares of the peer group delivered the past 10 years a gain of at around 598 percent.

Momentum biotech sector

stock graphs The sector trades now at 60 times the earnings per share. Currently the sector trades at 10,31 times the book value per share. Since 2012 the sector has a profit of 191 percent and since 2007 a higher of 598 percent.

For this year Galapagos's revenue will be around 201,15 million euros. This is according to the average of the analysts' estimates. This is hugely lower than 2017's revenue of 317,85 million euros.

Historical revenues and results Galapagos plus estimates 2019

stock prices

The analysts expect for 2019 a net loss of 208 million euros. The majority of the analysts expects for this year a loss per share of 3,77 euros. Based on this the price/earnings-ratio is -27,4.

For this year analysts don't expect the company to pay a dividend. The average dividend yield of the biotech companies equals a limited 0,5 percent.

Most recent target prices around 126 euros

The most recent recommendations for the biotech company are from Jefferies & Co., Goldman Sachs and Berenberg.

Galapagos's market value equals around 5,26 billion . The Galapagos stock was the past 12 months quite volatile. Since last May the stock is 19 percent higher. This year the stock price moved between 71 and 112 euro.

Historical stock prices Galapagos from 2007 till 2019

stock prices galapagos

At 10.42 the stock trades 0,58 percent lower at 103,3 euros. News Wire & Equity Research: +31 084-0032-842

Copyright B.V.
All rights reserved. Any redistribution, duplication or archiving prohibited. doesn't warrant the accuracy of any News Content provided and shall not be liable for any errors, inaccuracies or for any actions taken in reliance thereon.